Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival

Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.04/04/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news